More than 80 mutations in the skeletal muscle ryanodine receptor gene have been found to be associated with autosomal dominant forms of malignant hyperthermia and central core disease and recessive forms of multi-minicore disease. Studies on the functional effect of pathogenic dominant mutations have shown that they mostly affect intracellular calcium homeostasis, either by rendering the channel hypersensitive to activation (malignant hyperthermia) or by altering the amount of calcium released subsequent to physiological or pharmacological activation (central core disease). In this report we present for the first time data on the functional effect of 2 recently identified recessive ryanodine receptor 1 amino acid substitutions, P3527S and V4849I as well as that of R999H, another substitution identified in two siblings affected by multi-minicore disease. We studied the intracellular calcium homeostasis of EBV-transformed lymphoblastoid cells from the affected patients, their healthy relatives and control individuals. Our results show that the P3527S substitution at the homozygous state affects the amount of calcium released after pharmacological activation with 4-chloro-m-cresol and caffeine but did not affect the size of the thapsigargin sensitive Ca 2+ stores. The other substitutions had no effect on either the size of the intracellular calcium stores, or on the amount of calcium released after ryanodine receptor activation, however both the P3527S and V4849I had a small but significant effect on the resting [Ca 2+
INTRODUCTION
In skeletal muscle, calcium is a key second messenger of the excitation-contraction mechanism and the sarcoplasmic reticulum (SR) is the intracellular organelle involved in its regulation. The SR is endowed with numerous proteins involved in calcium handling, such as calsequestrin, a low affinity Ca back into the lumen of the SR [1] [2] [3] .
RYRs play a key role in Ca 2+ homeostasis since they function as calcium release channels through which luminal calcium is released thereby contributing actively to the elevation of the myoplasmic [Ca 2+ ], which is necessary for muscle contraction [4] [5] [6] . In view of its important role as a second messenger, the intracellular [Ca 2+ ] is finely regulated and any alteration in the proteins involved in Ca 2+ handling can potentially lead to pathological conditions. Examples of diseases linked to a dysregulation of Ca 2+ homeostasis include Malignant Hyperthermia (MH, OMIM 145600), Central Core Disease (CCD, OMIM 117000), Multi-minicore Disease (MmD OMIM 602771) and Brody's disease (OMIM 601003) [7] [8] [9] . The precise mechanism by which genetic alterations of these proteins trigger different pathophysiological patterns remains to be elucidated.
MmD is an autosomal recessive congenital myopathy characterized histologically by the presence of multiple cores, which are areas devoid of mitochondria, thus lacking oxidative enzymes and with highly disorganized sarcomeric structures. Multiple small cores can occur in both type 1 and type 2 fibres [10, 11] and do not run the entire length of the muscle fibre. In contrast, the histological pattern observed in biopsies from CCD patients is characterised by fibre type uniformity, with strong predominance of type 1 fibres, core lesions with clearly defined borders, occurring exclusively in type 1 fibres and running the entire length of the muscle fibre [12] [13] [14] . Both MmD and CCD are characterized by hypotonia during infancy, muscle weakness, delayed motor development; however, they differ in their pattern of muscle weakness and modes of inheritance. Clinical and histopathological overlap between CCD and MmD can occur [15, 16] , and were recently reported in two families where patients carried recessive homozygous RYR1 mutations [17, 18] .
The ryanodine receptor type 1 gene (RYR1), composed of 106 exons, maps to chromosome 19q13.1 and encodes for a protein of 5038 amino acids [19, 20] . More than 80 mutations in RYR1 have been genetically linked to MH and CCD [21, 22] . Disease-causing mutations appear to cluster in 3 defined regions of the RYR1: the cytoplasmic N-terminal domain 1 (Cys35-Arg614; region 1), the cytoplasmic central domain (Asp2129-Arg2458; region 2) and the C-terminal hydrophobic domain (Ile3916-Ala4942; region 3). In Malignant hyperthermia, a pharmacological disorder triggered by exposure to volatile anaesthetics and/or muscle relaxants in genetically predisposed individuals [23] [24] [25] , disease-linked mutations predominantly cluster in regions 1 and 2, whereas in CCD most RYR1 substitutions occur in the hydrophobic pore forming region 3. MmD is genetically heterogeneous; more than 50% of the cases presenting with the "classical" MmD phenotype harbour causative mutations in the selenoprotein N gene (SEPN1) [26] ; however, a significant proportion of the remaining cases carry recessive RYR1 mutations, distributed over all the gene.
Previous studies have demonstrated that EBV-immortalized human B-lymphocytes express the skeletal muscle isoform of the RYR [27, 28] and that they could be used as a model to test the effect of mutations on RYR function. In order to shed light on the functional impact of RYR1 mutations linked to MmD, in the present report we investigated the influence of naturally occurring RYR1 mutations identified in patients with MmD and/or CCD, on intracellular Ca 2+ homeostasis and pharmacological RYR activation, of EBV-immortalized Blymphocytes. The clinical genotypes and phenotypes of the two MmD cases have been described previously [17, 18] and are linked to the RYR1 mutations P3527S and V4849I. We also included in this study the functional effect of the R999H RYR1 substitution, which was identified at the heterozygous state, in a family in which two siblings were affected by MmD/CCD.
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EXPERIMENTAL PROCEDURES
MATERIALS
Thapsigargin and fura-2/AM were from Calbiochem. Caffeine was from Merck (Darmstadt, Germany), 4-chloro-m-cresol was from Fluka Chemicals (Buchs, Swizerland). ULTRASPEC RNA isolation system was from Biotecx laboratories (Houston, TX, U.S.A.). cDNA synthesis kit and Taq polymerase were from Roche Molecular Biochemicals. Tissue culture media and reagents were from Invitrogen. All other chemicals were reagent or the highest available grade.
METHODS
Patients
As SEPN1-mutations have been identified in 50% of classical severe MmD, haplotyping studies were first performed for every family and SEPN1 was clearly excluded as a candidate gene (data not shown).
Family 1: the P3527S substitution resulting from a C>T transition at position 10579 in exon 71 of the RYR1, was identified in 3 siblings from an Algerian consanguineous family [17] . In the present study, we immortalized lymphoblastoid cells from 2 of the affected daughters carrying the homozygous mutation and their healthy mother, heterozygous for this mutation. This mutation therefore, behaved as a recessive trait. In early childhood, minicores were observed in the biopsies of the siblings but when the probands were biopsied again during adult life, their muscle showed a typical CCD pattern. Patients were classified as recessive CCD with transient morphological presentation as MmD. A diagnosis of CCD secondary to a recessive RYR1 mutation was made.
Family 3: the R999H substitution resulting from a G>A transition at position 2996 in exon 24 of the RYR1 gene, was identified in the heterozygous state in a patient classified as MmD, with short cores present only in type 1 fibres. Her brother was mildly affected, also carried the mutation in the heterozygous state and presented short cores in both fibre types. The mother 6 had a normal CT scan, no signs of any neuromuscular disorder, but was later found to also harbour the R999H substitution at the heterozygous state.
Lymphoblastoid cell lines
Heparinized peripheral blood was obtained from healthy control individuals, family members of patients and patients with core myopathy carrying proven RYR1 mutations. Mononuclear cells were isolated and transformed with Epstein Barr Virus according to the protocol of Neitzel [29] . Cells were cultured in RPMI medium supplemented with 10% foetal bovine serum, 2 mM glutamine, 1 mM sodium pyruvate and 100 Units of penicillin and streptomycin.
Mutation screening
Total RNA was isolated using an RNA isolation kit. RNA was converted into cDNA using a commercially available kit following the manufacturers instructions. Approximately 100 ng of cDNA were used for each PCR amplification using a 2720 Thermal cycler (Applied 
Intracellular calcium measurements
Changes in the intracellular Ca indicator fura-2. Experiments were carried out on populations of cells, in an LS-50 Perkin Elmer spectrofluorimeter as previously described [28, 30, 31] or at the single cell level by digital imaging microscopy as previously described [32] . In the latter case, lymphoblastoid cells loaded with 5µM fura-2 were allowed to attach to poly-L-lysine treated glass coverslips for 10 minutes prior to the experiments. Individual cells were stimulated with a 12-way 100 mm diameter quartz micromanifold computer controlled 7 microperfuser (ALA Scientific) as described [32] . On-line (340 nm, 380 nm and ratio) measurements were recorded using a fluorescent Axiovert S100 TV inverted microscope (Carl Zeiss GmbH, Jena, Germany) equipped with a 40x oil-immersion Plan-NEOFLUAR objective (0.17 NA), filters (BP 340/380, FT 425, BP 500/530). The cells were analyzed using an Openlab imaging system and the average pixel value for each cell was measured at excitation wavelengths of 340 and 380 nm.
Statistical analysis
Statistical analysis was performed using the Student's t test for paired samples or using ANOVA when more than two groups were compared. Origin computer program (Microcal Software, Inc., Northampton, MA, USA) was used for statistical analysis and dose response curve generation. The EC 50 and Rmax values were calculated using the Origin program from sigmoidal curve fitting of all the data points.
RESULTS
RYR1-mutation analysis
The EBV-immortalised lymphoblastoid cells were analysed by RT-PCR to verify the presence of the different mutations at the transcriptional level. Figure 1 were treated with 400 nM thapsigargin, no significant differences were observed in the amount of Ca 2+ released, suggesting that none of the mutations affect the size of the thapsigarginsensitive intracellular stores ( fig. 3 B) .
Sensitivity of lymphoblastoid cell lines to pharmacological activation with RYR agonists
In the next set of experiments, we tested the sensitivities of lymphoblastoid cells to the RYR1 agonists 4-chloro-m-cresol (4-cmc) and caffeine. We first performed dose-response curves to 4-cmc by studying changes in [Ca 2+ ] i , in cell populations, in Ca 2+ -free Krebs Ringer and expressed these as % release with respect to the thapsigargin-sensitive pool (set as 100 %). Alternatively, the decrease of calcium released after the addition of 4-chloro-m-cresol, may reflect the fact that the mutation lies in proximity of the binding site for this agonist [44] .
As to the other two substitutions, under our experimental conditions we found that channels carrying the R999H substitution behave like their wild type counterpart both in terms of resting [Ca 2+ ], and total amount of Ca 2+ released after RYR1 activation. We would like to point out that genetic investigation into the family carrying the R999H substitution revealed that also the unaffected mother (with normal clinical examination and muscle CT scan) was a carrier of this substitution. Since the entire RYR1 of the proband was sequenced and found to contain no other amino acid substitutions, it is unlikely that this substitution alone is pathological at the heterozygous state and substitutions in other genes must be responsible for the MmD/CCD phenotype. As far as the V4849I mutation is concerned, lymphoblastoid cells carrying this substitution at the homozygous and heterozygous states behaved like wild type cells in terms of Ca 2+ store content and total amount of Ca 2+ released after pharmacological RYR activation; however they exhibited a small but significant increase in their resting [Ca 2+ ].
Sambuughin et al. [45] recently reported that the V4849I substitution may be causative of MH since it was found in one proband with a very strong IVCT. On the other hand, Monnier et al.
reported that this same substitution was also found in a control individual [46] . Our data show that cells carrying the V4849I substitution do not show an increased sensitivity to either 4-chloro-m-cresol, or caffeine, thus it is unlikely to be causative of MH when present (alone) either at the heterozygous and homozygous states. We are aware that lymphoblastoid cells do not express all the proteins which interact with the RYR1 in the sarcoplasmic reticulum, and we do not think that the conserved V4849I residue is involved in protein-protein interaction since it is predicted to be within a hydrophobic transmembrane domain (TM8) [19, 47] .
However, since the presence of this substitution affects the resting [Ca 2+ ] it may influence channel function in a way that could not be detected by our system. In conclusion, the present data strongly support a causative role for the P3527S RYR1 mutation at the homozygous level for the CCD/MmD phenotype; on the other hand our results
show that the functional properties of RYR1 carrying the R999H substitution are not different from controls and are most likely not causative of CCD/MmD. As to the V4849I substitution, our results show that its presence does not cause a shift in the sensitivity to pharmacologic activation of the ryanodine receptor, or cause alterations in the amount of thapsigargin, 4-chloro-m-cresol and caffeine-induced calcium release. However, since its presence affected the resting calcium concentration, the V4849I substitution may perturb the function of the ryanodine receptor channel in a way which was not discernable in the present study. Finally, these results confirm that lymphoblastoid cells can be used as a tool to study the effects of causative mutations vs polymorphisms among RYR1 substitutions, however one must keep in mind that these cells do not express all the proteins of the skeletal muscle sarcoplasmic reticulum involved in calcium homeostasis.
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